CA2129114A1 - Methods of treating inflammatory dermatoses - Google Patents

Methods of treating inflammatory dermatoses

Info

Publication number
CA2129114A1
CA2129114A1 CA002129114A CA2129114A CA2129114A1 CA 2129114 A1 CA2129114 A1 CA 2129114A1 CA 002129114 A CA002129114 A CA 002129114A CA 2129114 A CA2129114 A CA 2129114A CA 2129114 A1 CA2129114 A1 CA 2129114A1
Authority
CA
Canada
Prior art keywords
acid
tetramethyl
tetrahydro
corticosteroid
retinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002129114A
Other languages
English (en)
French (fr)
Inventor
Albert M. Kligman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2129114A1 publication Critical patent/CA2129114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002129114A 1992-02-07 1993-01-29 Methods of treating inflammatory dermatoses Abandoned CA2129114A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83282892A 1992-02-07 1992-02-07
US07/832,828 1992-02-07

Publications (1)

Publication Number Publication Date
CA2129114A1 true CA2129114A1 (en) 1993-08-19

Family

ID=25262717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002129114A Abandoned CA2129114A1 (en) 1992-02-07 1993-01-29 Methods of treating inflammatory dermatoses

Country Status (12)

Country Link
US (1) US5998395A (h)
EP (1) EP0625045A4 (h)
JP (1) JP2927961B2 (h)
KR (1) KR100282575B1 (h)
AU (1) AU667519B2 (h)
CA (1) CA2129114A1 (h)
CZ (1) CZ188394A3 (h)
FI (1) FI943625A0 (h)
NO (1) NO942913L (h)
NZ (1) NZ249379A (h)
WO (1) WO1993015740A1 (h)
ZA (1) ZA93811B (h)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344448B1 (en) 1992-09-11 2002-02-05 Stb Family Limited Partnership Composition for the treatment of hair loss
JPH08501552A (ja) * 1992-09-11 1996-02-20 ブラウン，サンドラ 脱毛治療方法および組成物
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
WO1996034601A1 (en) * 1995-05-05 1996-11-07 Braiman Mark S Treatment of psoriasis with 11-cis-retinoic acid
US6008254A (en) 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
EP1025857A4 (en) * 1997-10-22 2003-11-12 Eisai Co Ltd RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES
FR2761600B1 (fr) 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
RU2283098C2 (ru) * 2000-05-09 2006-09-10 Канека Корпорейшн Кожные композиции, содержащие кофермент q в качестве активного ингредиента
WO2002022113A2 (en) 2000-09-13 2002-03-21 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
KR20020027198A (ko) * 2000-10-02 2002-04-13 차알스 제이. 메츠 염증과 홍반의 완화방법
FR2823117A1 (fr) * 2000-11-14 2002-10-11 Pharmascience Lab Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
WO2002071025A2 (en) * 2001-03-02 2002-09-12 Spectra Systems Corporation Combinatorial chemistry and compound identification system
ES2188426B1 (es) * 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
US20030199488A1 (en) * 2002-04-23 2003-10-23 Trotta Gina M. Treatment of hyperproliferative disorders/inflammatory dermatoses
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
AU2003301516A1 (en) * 2002-10-24 2004-05-13 Goldstein, Jay A Antifungal formulations
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
ZA200604253B (en) * 2003-11-21 2007-10-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
NZ549159A (en) * 2004-02-19 2011-01-28 Chemaphor Inc Topical formulations for the treatment of skin conditions
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
JP2008514189A (ja) 2004-09-28 2008-05-08 ケマファー インコーポレイティッド 体重増加および飼料効率を促進するための組成物および方法
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
AU2008316225B2 (en) 2007-10-26 2014-06-19 Avivagen Inc. Compositions and methods for enhancing immune response
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
CA2975313C (en) 2009-04-30 2020-06-30 Avivagen Inc. Methods and compositions for improving the health of animals
JP5967657B2 (ja) 2009-10-20 2016-08-10 ディスカバリー パートナーズ, エルエルシーDiscovery Partners, Llc 皮膚化粧料組成物
ES2378028B1 (es) 2012-02-22 2013-02-18 Ignacio Umbert Millet Composición cosmética para el rejuvenecimiento de la piel y procedimiento y usos correspondientes
CA3077331A1 (en) * 2017-09-28 2019-04-04 Johnson & Johnson Consumer Inc. Cosmetic compositions and method of treating the skin
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4126693A (en) * 1975-11-03 1978-11-21 Johnson & Johnson Retinoic acid derivatives in the treatment of acne
ZA77678B (en) * 1977-02-07 1978-09-27 S Fourie Pharmaceutical composition and use thereof
US4487782A (en) * 1982-03-26 1984-12-11 Ortho Pharmaceutical Corporation Topical treatment of non-inflammatory acne
US4889847A (en) * 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy

Also Published As

Publication number Publication date
AU667519B2 (en) 1996-03-28
AU3585493A (en) 1993-09-03
US5998395A (en) 1999-12-07
KR950700069A (ko) 1995-01-16
NO942913D0 (h) 1994-08-05
WO1993015740A1 (en) 1993-08-19
NZ249379A (en) 1998-07-28
JP2927961B2 (ja) 1999-07-28
NO942913L (no) 1994-10-05
ZA93811B (en) 1993-09-10
JPH07505617A (ja) 1995-06-22
FI943625L (fi) 1994-08-04
EP0625045A1 (en) 1994-11-23
FI943625A7 (fi) 1994-08-04
FI943625A0 (fi) 1994-08-04
EP0625045A4 (en) 1995-01-18
KR100282575B1 (ko) 2001-02-15
CZ188394A3 (en) 1996-02-14

Similar Documents

Publication Publication Date Title
CA2129114A1 (en) Methods of treating inflammatory dermatoses
US4889847A (en) Prevention of glucocorticoid-induced skin atrophy
US7939516B2 (en) Topical skin care composition
US20080038219A1 (en) Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof
US5019569A (en) Reversal of glucocorticoid-induced skin atrophy
US20070009607A1 (en) Antibacterial/anti-infalmmatory composition and method
Orfanos et al. Oral treatment of keratosis follicularis with a new aromatic retinoid
JP2007308430A (ja) ニキビ治療剤
Olsen Therapy of acne
Handojo The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris
JP3839502B2 (ja) 湿疹・皮膚炎群治療剤
US9642877B1 (en) Method of administration of chromium and magnesium sulfate for treatment of acne
NZ235156A (en) Cosmetic treatment of striae distensae using a retinoid compound
US20220233489A1 (en) Kits for dermal care
NZ286443A (en) Treatment of inflammatory dermatoses other than psoriasis using a retinoid and a corticosteroid
Rajka Emollient therapy in atopic dermatitis
US11458114B2 (en) Methods and compositions for enhancing synthesis secretion and transport of collagen to increase wound strength
Massi et al. The effectiveness of autologous serum and single-dose oral doxycycline in the treatment of acne vulgaris: a pilot clinical trial
Massi et al. The Effectiveness of Autologous Serum and Single-dose Oral Doxycycline in the Treatment of Acne Vulgaris: A Pilot Clinical Trial. Open Access Maced J Med Sci. 2021 Nov 28; 9 (B): 1602-1606
WO2024263134A1 (en) Safe and effective drug formulation used for the treatment of psoriasis
KR100189663B1 (ko) 팽창선 병변의 예방 및 이의 크기를 감소시키기 위한 약제학적 조성물
CA2963110A1 (en) Method of administration of chromium and magnesium sulfate for treatment of acne
HK40037195B (en) Topical pharmaceutical compositions for treating skin conditions
HK40037195A (en) Topical pharmaceutical compositions for treating skin conditions
Matt et al. Newer retinoids for psoriasis—Early clinical studies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued